📰 Core Inc News
Page 9 - Core Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Core Inc. Real-time updates on events, politics, business and more.
June 9, 2022
/PRNewswire/ -- According to the new market research report "Energy Recovery Ventilator Core Market by Material Type (Engineered Resin, Fibrous Paper), Shape...
June 9, 2022
CHICAGO, June 9, 2022 /PRNewswire/ -- According to the new market research report "Energy Recovery Ventilator Core Market by Material Type (Engineered Resin, Fibrous Paper), Shape (Square, Diamond
June 6, 2022
/PRNewswire/ -- According to Coherent Market Insights, the global vagus nerve stimulators market is estimated to be valued at US$ 628.3 million in 2022 and is...
June 6, 2022
/PRNewswire/ -- electroCore, a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve...
June 2, 2022
/PRNewswire/ -- According to the new market research report "Nerve Repair and Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation,...
June 2, 2022
CHICAGO, June 2, 2022 /PRNewswire/ -- According to the new market research report "Nerve Repair and Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve
June 1, 2022
ElectroCore, Inc. (NASDAQ:ECOR – Get Rating) Director Trevor J. Moody purchased 39,478 shares of electroCore stock in a transaction that occurred on Tuesday, May 31st. The stock was acquired at an average cost of $0.44 per share, with a total value of $17,370.32. Following the acquisition, the director now directly owns 423,455 shares in the […]
May 21, 2022
This report studies the Digital Migraine Treatment Devices Market with many aspects of the industry like the market size, market status, market trends and
May 20, 2022
This report studies the Semiconductor for Robotics Market with many aspects of the industry like the market size, market status, market trends and forecast, the
May 17, 2022
Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial